Bexarotene (Targretin) is a retinoid X receptor (RXR) agonist that has applications for treatment of T cell lymphoma and proposed mechanisms of action in Alzheimer's disease that have been the subject of recent controversy. Carbon-11 labeled bexarotene ([ 11 Ccarbonyl]4- [1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid) was synthesized using a Cu-mediated cross-coupling reaction employing an arylboronate precursor 1 and [ 11 C]carbon dioxide under atmospheric pressure in 15 ± 2% uncorrected radiochemical yield (n = 3), based on [ 11 C]CO 2 . Judicious choice of solvents, catalysts, and additives, as well as precursor concentration and purity of [ 11 C]CO 2 , enabled the preparation of this 11 C-labeled carboxylic acid. Formulated [ 11 C]bexarotene was isolated (>37 mCi) with >99% radiochemical purity in 32 min. Preliminary positron emission tomography−magnetic resonance imaging revealed rapid brain uptake in nonhuman primate in the first 75 s following intravenous administration of the radiotracer (specific activity >0.3 Ci/μmol at time of injection), followed by slow clearance (Δ = −43%) over 60 min. Modest uptake (SUV max = 0.8) was observed in whole brain and regions with high RXR expression. KEYWORDS: Bexarotene, targretin, positron emission tomography, carbon-11, carbon dioxide fixation, retinoid X receptor, Alzheimer's disease R etinoid X receptors (RXRs) function as key transcription factors inasmuch as they are the heterodimeric partners for most nuclear receptors, including retinoic acid receptors (RARs), peroxisome proliferator-activated receptors (PPARs), vitamin D receptor, and thyroid hormone receptor. 1 Retinoid X ligands (e.g., 9-cis retinoic acid, Figure 1) are small lipophilic hormones, which, when bound to a heterodimeric or a homodimeric (i.e., RXR-RXR fusion) receptor, cause it to bind a transcription complex on DNA and to promote expression of target genes. RXRs are found ubiquitously and differentially in mammalian cells, including in both glial and neuronal brain tissue. 2 Defective retinoid signaling and deficiency of apolipoprotein E (ApoE) are closely associated with Alzheimer's disease (AD). 3 Bexarotene (4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, Figure 1), an FDA-approved selective RXR agonist, 4 has recently been demonstrated to induce clearance of β-amyloid from the brains of murine AD models through activation of the APOE gene, which is the most indicative genetic risk factor for late-onset AD. 5 In vitro and in vivo studies also suggest that bexarotene is acting on RXRs, and not directly on β-amyloid or by compromising the blood−brain barrier. 6 A transgenic mouse model of AD (Tg2576) exhibited reversal of cognitive and behavioral degradation with the administration of bexarotene. 5 These findings have proven to be controversial, however, as several laboratories have struggled to reproduce both the scope and magnitude of the in vivo results. 7−11 An additional caveat to these results is that the bexarotene dose used to achieve these effect...